<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DNA methyltransferase inhibitor, 5-<z:chebi fb="0" ids="2038">azacitidine</z:chebi> (AC) is effective in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and can induce re-expression in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed the methylation of 25 tumor suppressor genes in AC-treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Hypermethylation of CDKN2B, FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients </plain></SENT>
<SENT sid="3" pm="."><plain>In concordance with the clinical response, a lack of or decreased methylation in 4 patients with hematologic improvements and persistent methylation in 4 others with no response was observed </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of CDKN2B, IGSF4, and ESR1 was significantly reduced in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Our results suggest that methylation changes contribute to disease pathogenesis and may serve as marker to monitor the efficacy of treatments </plain></SENT>
</text></document>